🇪🇺 TAK-577 in European Union

EMA authorised TAK-577 on 31 August 2018

Marketing authorisation

EMA — authorised 31 August 2018

  • Application: EMEA/H/C/004454
  • Marketing authorisation holder: Baxalta Innovations GmbH
  • Local brand name: Veyvondi
  • Indication: Prevention and treatment of haemorrhage or surgical bleeding in adults (age 18 years and older) with von Willebrand disease (VWD), when desmopressin (DDAVP) treatment alone is ineffective or contraindicated. Veyvondi should not be used in the treatment of Haemophilia A.
  • Status: approved

Read official source →

Frequently asked questions

Is TAK-577 approved in European Union?

Yes. EMA authorised it on 31 August 2018.

Who is the marketing authorisation holder for TAK-577 in European Union?

Baxalta Innovations GmbH holds the EU marketing authorisation.